In addition to their direct effect on tumors, PI3K/AKT/mTOR and MAPK/MEK/ERK inhibitors have been shown to modulate the tumor microenvironment, increase immunogenicity, and thus potentially facilitate increased sensitivity to immunotherapy. Here, MAP2K7 is linked to neoplasm.